Commercial Launch of AxisBiotix-PsT

RNS Number : 6358Q
SkinBioTherapeutics PLC
29 October 2021

29 October 2021


SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")


Commercial Launch of AxisBiotix-Ps™ Psoriasis Food Supplement

· AxisBiotix-Ps™ successfully launches today on World Psoriasis Day - 29 October 2021

· Product now on sale online at

· AxisBiotix-Ps™ now being shipped to the UK and US, with a subscription price per sachet of £1.50 / $2.00

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, has today announced the commercial launch of AxisBiotix-Ps™, its probiotic food supplement to help alleviate the symptoms associated with psoriasis, on World Psoriasis Day - 29 October 2021. The launch follows the highly positive results from its  consumer study  which concluded in May 2021.


Stuart Ashman, CEO of SkinBioTherapeutics, said:

"The launch of our first commercial product is a momentous occasion for SkinBioTherapeutics. The interest in AxisBiotix-Ps™, and overwhelmingly positive response from participants, has been hugely encouraging. We're delighted to introduce our product to the market on the most important of days for the global psoriasis community, as planned.

"Since the exciting results from the consumer study, announced back in May this year, we have seen an growing interest in our product. We have been working hard ever since to establish a reliable supply chain to ensure a continuous supply to all our customers upon launch.

"I want to thank the team for their efforts to make the launch possible in Q4 of 2021, on schedule."


As previously announced in the progress update , commercialisation will start today in the UK and the US markets, with customers able to access the product at .


AxisBiotix-Ps will be sold primarily on a subscription basis and is priced per sachet (including VAT and excluding shipping and any duty costs) in the US at $2.00 (USD), in the UK £1.50 (GBP), and in due course in Europe at €1.80 (EUR). As demonstrated in the consumer study, it can take 3-4 weeks for the benefits of AxisBiotix-Ps to be achieved. Consequently, for an initial period, customers will receive 28 free sachets with their first purchase. The product is sold in boxes containing 28 sachets with customers able to subscribe on a 4 weekly or 8 weekly basis.


In May 2021, SkinBioTherapeutics reported on the outcomes of the study for participants that self-identified as suffering from psoriasis. The results were very positive and provided definitive support for the commercial development of AxisBiotix-Ps™ as a probiotic food supplement to help alleviate the symptoms of psoriasis. Of participants that completed the study, 76% reported a reduction in itchiness and 73% reported that their skin felt less irritable. For the full report, please see HERE .


For more information please contact:

SkinBioTherapeutics plc

Stuart J . Ashman, CEO

Doug Quinn, CFO

Tel: +44 (0) 161 468 2760

Cenkos Securities Plc (Nominated Adviser & Broker)

Giles Balleny, Max Gould (Corporate Finance)

Michael Johnson, Dale Bellis (Sales)

Tel: +44 (0) 20 7397 8900

Instinctif Partners (financial press)

Melanie Toyne-Sewell / Nathan Billis 

Tel: +44 (0) 20 7457 2020

[email protected]



About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: .



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.